Research Progress of Drugs for Maintenance Treatment for Platinum-Sensitive Recurrent Ovarian Cancer

doi:10.12280/gjfckx.20220004

Abstract

Abstract:

As the worst prognosis malignant tumor in gynecological diseases, ovarian cancer is more insidious and difficult to be diagnosed in the early stage. The recurrence rate of ovarian cancer patients is extremely high after the standard treatment regimen of comprehensive staging surgical and chemotherapy with platinum or paclitaxel drugs. Patients with recurrence are prone to develop platinum resistance after multiple chemotherapy sessions, and the therapeutic effect is getting worse. Therefore, how to reduce tumor recurrence, prolong patients′ survival time and improve quality of life has always been a difficult point in clinical treatment of ovarian cancer. For patients with platinum-sensitive recurrent ovarian cancer, they need to be treated with maintenance therapy after surgery plus chemotherapy. Molecular targeted drug regimens such as anti-angiogenic drugs and poly (ADP-ribose) polymerase inhibitors are used to maintain the efficacy of post-chemotherapy treatment in order to prolong progression-free survival and delay recurrence, and improve survival and quality of life. The article reviews the current pharmacological approaches related to maintenance therapy for platinum-sensitive recurrent ovarian cancer and looks forward to the application of maintenance therapy in the treatment of platinum-sensitive recurrent ovarian cancer.

Key words: Ovarian neoplasms, Antineoplastic combined chemotherapy protocols, Antiangiogenic agents, Bevacizumab, Poly(ADP-ribose) polymerase, Drug resistance, neoplasm

CHANG Xin, HAN Lu. Research Progress of Drugs for Maintenance Treatment for Platinum-Sensitive Recurrent Ovarian Cancer[J]. Journal of International Obstetrics and Gynecology, 2022, 49(4): 382-387.

References 30

[1]	Henderson JT, Webber EM, Sawaya GF. Screening for Ovarian Cancer: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force[J]. JAMA, 2018, 319(6):595-606. doi: 10.1001/jama.2017.21421. doi: 10.1001/jama.2017.21421 pmid: 29450530
[2]	Reid BM, Permuth JB, Sellers TA. Epidemiology of ovarian cancer: a review[J]. Cancer Biol Med, 2017, 14(1):9-32. doi: 10.20892/j.issn.2095-3941.2016.0084. doi: 10.20892/j.issn.2095-3941.2016.0084
[3]	Oaknin A, Oza AM, Lorusso D, et al. Maintenance treatment with rucaparib for recurrent ovarian carcinoma in ARIEL3, a randomized phase 3 trial: The effects of best response to last platinum-based regimen and disease at baseline on efficacy and safety[J]. Cancer Med, 2021, 10(20):7162-7173. doi: 10.1002/cam4.4260. doi: 10.1002/cam4.4260
[4]	牛星燕, 张冬萍, 李飞霞, 等. 卵巢恶性肿瘤化疗研究进展[J]. 国际妇产科学杂志, 2020, 47(2):125-128. doi: 10.3969/j.issn.1674-1870.2020.02.001. doi: 10.3969/j.issn.1674-1870.2020.02.001
[5]	Ghoneum A, Afify H, Salih Z, et al. Role of tumor microenvironment in ovarian cancer pathobiology[J]. Oncotarget, 2018, 9(32):22832-22849. doi: 10.18632/oncotarget.25126. doi: 10.18632/oncotarget.25126 pmid: 29854318
[6]	唐彧, 郑维维, 钱程, 等. 免疫细胞调节肿瘤血行转移的研究进展[J]. 中国药理学通报, 2021, 37(12):1653-1658. doi: 10.3969/j.issn.1001-1978.2021.12.006. doi: 10.3969/j.issn.1001-1978
[7]	Ramjiawan RR, Griffioen AW, Duda DG. Anti-angiogenesis for cancer revisited: Is there a role for combinations with immunotherapy?[J]. Angiogenesis, 2017, 20(2):185-204. doi: 10.1007/s10456-017-9552-y. doi: 10.1007/s10456-017-9552-y pmid: 28361267
[8]	Aghajanian C, Goff B, Nycum LR, et al. Final overall survival and safety analysis of OCEANS, a phase 3 trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent ovarian cancer[J]. Gynecol Oncol, 2015, 139(1):10-16. doi: 10.1016/j.ygyno.2015.08.004. doi: 10.1016/j.ygyno.2015.08.004 pmid: 26271155
[9]	Coleman RL, Brady MF, Herzog TJ, et al. Bevacizumab and paclitaxel-carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology/Gynecologic Oncology Group study GOG-0213): a multicentre, open-label, randomised, phase 3 trial[J]. Lancet Oncol, 2017, 18(6):779-791. doi: 10.1016/S1470-2045(17)30279-6. doi: S1470-2045(17)30279-6 pmid: 28438473
[10]	Tewari KS, Burger RA, Enserro D, et al. Final Overall Survival of a Randomized Trial of Bevacizumab for Primary Treatment of Ovarian Cancer[J]. J Clin Oncol, 2019, 37(26):2317-2328. doi: 10.1200/JCO.19.01009. doi: 10.1200/JCO.19.01009
[11]	González Martín A, Oza AM, Embleton AC, et al. Exploratory outcome analyses according to stage and/or residual disease in the ICON7 trial of carboplatin and paclitaxel with or without bevacizumab for newly diagnosed ovarian cancer[J]. Gynecol Oncol, 2019, 152(1):53-60. doi: 10.1016/j.ygyno.2018.08.036. doi: S0090-8258(18)31166-1 pmid: 30449719
[12]	荆立华, 魏晶, 李健华, 等. 多普勒超声血流阻力指数与卵巢肿瘤患者血清ANGPTL4、Ang-2表达的相关性分析[J]. 中国计划生育学杂志, 2020, 28(9):1490-1493. doi: 10.3969/j.issn.1004-8189.2020.09.039. doi: 10.3969/j.issn.1004-8189.2020.09.039
[13]	Conway GD, Buzza MS, Martin EW, et al. PRSS21/testisin inhibits ovarian tumor metastasis and antagonizes proangiogenic angiopoietins ANG2 and ANGPTL4[J]. J Mol Med(Berl), 2019, 97(5):691-709. doi: 10.1007/s00109-019-01763-3. doi: 10.1007/s00109-019-01763-3
[14]	Wu Y, Gao J, Liu X. Deregulation of angiopoietin-like 4 slows ovarian cancer progression through vascular endothelial growth factor receptor 2 phosphorylation[J]. Cancer Cell Int, 2021, 21(1):171. doi: 10.1186/s12935-021-01865-4. doi: 10.1186/s12935-021-01865-4
[15]	王柯若, 李慧锴, 秦宇. DNA损伤应答通路抑制剂治疗卵巢癌的研究进展[J]. 国际妇产科学杂志, 2020, 47(4):437-442. doi: 10.3969/j.issn.1674-1870.2020.04.018. doi: 10.3969/j.issn.1674-1870.2020.04.018
[16]	储慧慧, 刘倩. 卵巢癌临床治疗的研究进展[J]. 国际妇产科学杂志, 2021, 48(4):443-447,466. doi: 10.12280/gjfckx.20210103. doi: 10.12280/gjfckx.20210103
[17]	Ledermann JA, Harter P, Gourley C, et al. Overall survival in patients with platinum-sensitive recurrent serous ovarian cancer receiving olaparib maintenance monotherapy: an updated analysis from a randomised, placebo-controlled, double-blind, phase 2 trial[J]. Lancet Oncol, 2016, 17(11):1579-1589. doi: 10.1016/S1470-2045(16)30376-X. doi: S1470-2045(16)30376-X pmid: 27617661
[18]	Poveda A, Floquet A, Ledermann JA, et al. Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial[J]. Lancet Oncol, 2021, 22(5):620-631. doi: 10.1016/S1470-2045(21)00073-5. doi: 10.1016/S1470-2045(21)00073-5
[19]	Riaz N, Blecua P, Lim RS, et al. Pan-cancer analysis of bi-allelic alterations in homologous recombination DNA repair genes[J]. Nat Commun, 2017, 8(1):857. doi: 10.1038/s41467-017-00921-w. doi: 10.1038/s41467-017-00921-w
[20]	Sandro P, Amit O, Geoff H, et al. ORZORA: Maintenance olaparib in patients with platinum-sensitive relapsed ovarian cancer: outcomes by somatic and germline BRCA and other homologous recombination repair gene mutation status[J]. Gynecol Oncol, 2021, 162(S1):S29. doi: 10.1016/S0090-8258(21)00700-9. doi: 10.1016/S0090-8258(21)00700-9
[21]	Mirza MR, Monk BJ, Herrstedt J, et al. Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer[J]. N Engl J Med, 2016, 375(22):2154-2164. doi: 10.1056/NEJMoa1611310. doi: 10.1056/NEJMoa1611310
[22]	Wu XH, Zhu JQ, Yin RT, et al. Niraparib maintenance therapy in patients with platinum-sensitive recurrent ovarian cancer using an individualized starting dose (NORA): a randomized, double-blind, placebo-controlled phase III trial[J]. Ann Oncol, 2021, 32(4):512-521. doi: 10.1016/j.annonc.2020.12.018. doi: 10.1016/j.annonc.2020.12.018 pmid: 33453391
[23]	Coleman RL, Oza AM, Lorusso D, et al. Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial[J]. Lancet, 2017, 390(10106):1949-1961. doi: 10.1016/S0140-6736(17)32440-6. doi: S0140-6736(17)32440-6 pmid: 28916367
[24]	Li N, Zhang YZ, Wang J, et al. Fuzuloparib maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer: a multicenter, randomized, double-blind, placebo-controlled, phase III trial[J]. Gynecol Oncol, 2021, 162(S1):1. doi: 10.1016/S0090-8258(21)00752-6. doi: 10.1016/S0090-8258(21)00752-6
[25]	Banerjee S, Gonzalez-Martin A, Harter P, et al. First-line PARP inhibitors in ovarian cancer: summary of an ESMO Open-Cancer Horizons round-table discussion[J]. ESMO Open, 2020, 5(6):e001110. doi: 10.1136/esmoopen-2020-001110. doi: 10.1136/esmoopen-2020-001110
[26]	Mirza MR, Åvall Lundqvist E, Birrer MJ, et al. Niraparib plus bevacizumab versus niraparib alone for platinum-sensitive recurrent ovarian cancer (NSGO-AVANOVA2/ENGOT-ov24): a randomised, phase 2, superiority trial[J]. Lancet Oncol, 2019,20(10):1409-1419. doi: 10.1016/S1470- 2045(19)30515-7.
[27]	Lee SP, Hsu HC, Tai YJ, et al. Bevacizumab Dose Affects the Severity of Adverse Events in Gynecologic Malignancies[J]. Front Pharmacol, 2019, 10:426. doi: 10.3389/fphar.2019.00426. doi: 10.3389/fphar.2019.00426
[28]	中华医学会妇科肿瘤学分会. 卵巢癌PARP抑制剂临床应用指南[J]. 中国医学前沿杂志(电子版), 2020, 12(5):29-37. doi: 10.12037/YXQY.2020.05-06. doi: 10.12037/YXQY.2020.05-06
[29]	中国抗癌协会妇科肿瘤专业委员会, 吴小华, 温灏. PARP抑制剂不良反应管理的中国专家共识(2021年版)[J]. 中国实用妇科与产科杂志, 2021, 37(11):1119-1130. doi: 10.19538/j.fk2021110111. doi: 10.19538/j.fk2021110111
[30]	Yamamoto TM, McMellen A, Watson ZL, et al. Activation of Wnt signaling promotes olaparib resistant ovarian cancer[J]. Mol Carcinog, 2019, 58(10):1770-1782. doi: 10.1002/mc.23064. doi: 10.1002/mc.23064